Clinical Trials Logo

Bronchiectasis clinical trials

View clinical trials related to Bronchiectasis.

Filter by:

NCT ID: NCT01792427 Completed - Clinical trials for Non-cystic Fibrosis Bronchiectasis

Mortality in Non-cystic Fibrosis Bronchiectasis

Start date: June 2006
Phase: N/A
Study type: Observational

In this study we analyzed the overall survival for all newly diagnosed patients with non-cystic fibrosis bronchiectasis from June 2006 onwards. The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa and evaluate the impact on survival of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension.

NCT ID: NCT01769898 Completed - Bronchiectasis Clinical Trials

The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis

Start date: July 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine the efficacy and safety of 24 weeks treatment with theophylline plus low-dose formoterol-budesonide in subjects with bronchiectasis.

NCT ID: NCT01764841 Completed - Bronchiectasis Clinical Trials

Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

RESPIRE 1
Start date: May 2, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.

NCT ID: NCT01684683 Completed - Bronchiectasis Clinical Trials

The Effect of Theophylline in the Treatment of Bronchiectasis

Start date: November 2012
Phase: Phase 4
Study type: Interventional

Theophylline was well recommended in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. However, there is no supporting evidence for their efficacy in the treatment of bronchiectasis. Our hypothesis is that theophylline will play a role in bronchiectasis. Our purpose is to examine the efficacy and safety of 24 weeks treatment with theophylline in subjects with non-cystic fibrosis bronchiectasis.

NCT ID: NCT01615484 Completed - Cystic Fibrosis Clinical Trials

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

Start date: September 2013
Phase: N/A
Study type: Interventional

The purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and perfused with a lung perfusion solution (Steen solution™, made by Vitrolife). This ventilation and perfusion will be done outside the body (ex-vivo) in a modified cardiopulmonary bypass circuit (the kind of device used routinely during most heart surgeries). The purpose of performing ex-vivo perfusion and ventilation is to learn how well the lungs work, and whether they are likely safe to transplant.

NCT ID: NCT01578681 Completed - Bronchiectasis Clinical Trials

ELTGOL and Bronchiectasis. Respiratory Therapy

ELTGOLBQ
Start date: September 2011
Phase: N/A
Study type: Interventional

The ELTGOL technique improves mucociliary clearance in adult patients with bronchiectasis. Primary objective: -To evaluate the efficacy of ELTGOL in stable state patients with bronchiectasis compared to placebo. Secondary objectives: - To evaluate the level of knowledge of airway clearance techniques and adherence to them in patients with bronchiectasis. - To assess the side effects during the procedure: oxygen desaturation, increased dyspnea and hemoptysis.

NCT ID: NCT01569009 Completed - Bronchiectasis Clinical Trials

Physical Activity in Bronchiectasis

PhAB
Start date: June 2012
Phase: N/A
Study type: Observational

The primary aim of this study is to examine the physical activity levels of patients with bronchiectasis. Subsidiary aims are: 1. To examine whether there is a relationship between the physical activity levels of patients with bronchiectasis and clinical phenotype (disease severity, exercise capacity, quality of life or other symptoms of their disease). The investigators also want to explore the relationship between physical activity levels and readiness to change physical activity behaviour (stages of change, self-efficacy, decisional balance and processes of change). 2. To assess the feasibility and acceptability of the physical activity assessment tools: ActiGraph, ActivPAL, pedometer and the International Physical Activity Questionnaire. Hypothesis: Patients with bronchiectasis will have low levels of physical activity, and this is related to their clinical phenotype (disease severity, exercise capacity, quality of life and other symptoms of their disease) and also their readiness to change physical activity behaviour (stages of change, self-efficacy, processes of change and decisional balance).

NCT ID: NCT01515007 Completed - Clinical trials for Non Cystic Fibrosis Bronchiectasis

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Start date: March 31, 2014
Phase: Phase 3
Study type: Interventional

This study (ARD-3150-1201, ORBIT-3) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic fibrosis (non-CF) bronchiectasis with a history of pulmonary exacerbations and chronic P. aeruginosa infections.

NCT ID: NCT01480882 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage

LEGA
Start date: December 2011
Phase: Phase 2/Phase 3
Study type: Interventional

A Malaysian company by name Formedic Technologies SDN BHD has devised a hand held machine which is supposed to mimic the chest percussion performed by professional physiotherapist to mobilize sputum through the respiratory passage. The aim of this study is to compare the effectiveness and safety of this mechanical percussion device in the treatment of airway clearance with conventional chest physiotherapy carried out by qualified physiotherapists in patients suffering from bronchiectasis or Chronic obstructive Pulmonary disease (COPD).

NCT ID: NCT01463371 Completed - Bronchiectasis Clinical Trials

Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis

Start date: October 2006
Phase: N/A
Study type: Interventional

The mechanism by which macrolide antibiotics have immune modifying effects independent from its antibacterial activity has not been well established. In the present work, the investigators will analyze the effect of long-term treatment with azithromycin (250 mg three times per week during three months) on airway oxidative stress markers in exhaled breath condensate of adult patients with stable non-CF bronchiectasis.